Posted by Michael Wonder on 27 Jan 2026
Innovent announces IBI3003 (GPRC5D/BCMA/CD3 trispecific antibody) receives fast track designation from the US FDA for relapsed or refractory multiple myeloma
27 January 2026 - Innovent Biologics announced that its anti-GPRC5D/BCMA/CD3 tri-specific antibody IBI3003 has received fast track designation from the US FDA.
This designation applies to the treatment of relapsed or refractory multiple myeloma, in patients who have received four or more lines of previous anti-myeloma therapies, that include at least a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.
